Growth & profitability
- Revenue has grown 50.0% per year over the past 5 years.
- Operating margin has expanded, at -363.5% in the latest year.
MRKR Financials Marker Therapeutics, Inc.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $4M | -$12M | 0.0% | -363.5% | — | — | $16M |
| 2024 | $7M | -$11M | 0.0% | -168.7% | — | — | $19M |
| 2023 | $3M | -$8M | 0.0% | -440.4% | — | — | $15M |
| 2022 | $4M | -$30M | 0.0% | -563.3% | — | — | $12M |
| 2021 | $1M | -$42M | 0.0% | -3179.3% | — | — | $42M |
| 2020 | $466785 | -$29M | 0.0% | -6188.2% | — | — | $21M |
| 2019 | $213194 | -$21M | 0.0% | -10567.3% | -$19M | — | $44M |
| 2018 | — | -$148M | — | — | -$15M | — | $62M |
| 2017 | — | -$11M | — | — | -$8M | — | $5M |
| 2016 | — | -$2M | — | — | — | — | — |
| 2015 | — | -$34M | — | — | — | — | — |
| 2014 | — | -$31M | — | — | — | — | — |
| 2014 | — | -$84M | — | — | -$18M | — | — |
| 2013 | — | -$6M | — | — | -$913209 | — | — |
| 2013 | — | -$50M | — | — | -$17M | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $751691 | -$3M | 0.0% | -541.8% | — | — | $15M |
| Dec '25 | $1M | -$2M | 0.0% | -170.7% | — | — | $16M |
| Sep '25 | $1M | -$2M | 0.0% | -173.3% | — | — | $18M |
| Jun '25 | $861184 | -$4M | 0.0% | -494.8% | — | — | $10M |
| Mar '25 | $349104 | -$4M | 0.0% | -1420.1% | — | — | $14M |
| Dec '24 | $2M | -$4M | 0.0% | -171.5% | — | — | $19M |
| Sep '24 | $2M | -$2M | 0.0% | -124.6% | — | — | $9M |
| Jun '24 | $1M | -$2M | 0.0% | -197.4% | — | — | $8M |
| Mar '24 | $1M | -$2M | 0.0% | -204.9% | — | — | $11M |
| Dec '23 | $1M | -$3M | 0.0% | -278.1% | — | — | $15M |
| Sep '23 | $257606 | -$3M | 0.0% | -1242.2% | — | — | $17M |
| Jun '23 | $762658 | $3M | 0.0% | -542.1% | — | — | $18M |
| Mar '23 | $1M | -$5M | 0.0% | -349.1% | — | — | $6M |
| Dec '22 | $759143 | -$4M | 0.0% | -400.3% | — | — | $12M |
| Sep '22 | $999571 | -$7M | 0.0% | -582.9% | — | — | $18M |
| Jun '22 | $790508 | -$9M | 0.0% | -666.5% | — | — | $26M |
| Mar '22 | $964322 | -$10M | 0.0% | -1015.7% | — | — | $29M |
| Dec '21 | — | -$10M | — | — | — | — | $42M |
| Sep '21 | — | -$12M | — | — | — | — | $49M |
| Jun '21 | — | -$11M | — | — | — | — | $57M |
Valuation over time
How the market has priced MRKR against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has risen from 3.5× (Mar '23) to 6.2× (Jun '26).
P/S
Frequently asked questions
Is MRKR growing its revenue and profit?
Over the past 5 years, Marker Therapeutics, Inc.'s revenue has grown 50.0% per year. These are computed facts, not advice.
How much debt does MRKR have?
As of FY2025, Marker Therapeutics, Inc. reported — of total debt against $16M of cash.
What is MRKR's profit margin?
In FY2025, gross margin was —, operating margin -363.5%, and net margin -343.0%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.